Beam Therapeutics Inc. (BEAM) –
-
Form ARS Beam Therapeutics Inc. For: Dec 31
-
Form DEFA14A Beam Therapeutics Inc.
-
Form DEF 14A Beam Therapeutics Inc. For: Jun 05
-
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
-
Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe
-
Form 144 Beam Therapeutics Inc. Filed by: Burrell Terry-Ann
-
Form 144 Beam Therapeutics Inc. Filed by: Simon Amy
-
Form 144 Beam Therapeutics Inc. Filed by: Bellon Christine
-
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Simon Amy
-
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Bellon Christine
-
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Burrell Terry-Ann
-
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Evans John M.
-
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Ciaramella Giuseppe
-
Form 144 Beam Therapeutics Inc. Filed by: Simon Amy
-
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Burrell Terry-Ann
-
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Bellon Christine
-
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Ciaramella Giuseppe
-
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Simon Amy
-
Form 4 Beam Therapeutics Inc. For: Mar 28 Filed by: Evans John M.
-
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
-
Beam Therapeutics Inc. (BEAM) Announces Clearance of Clinical Trial Authorisation Application for BEAM-302
-
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-
2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers
-
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
-
Beam Therapeutics Inc. (BEAM) Files Mixed Shelf
-
Form S-3ASR Beam Therapeutics Inc.
-
Beam Therapeutics Inc (BEAM) PT Raised to $42 at Barclays
-
Beam Therapeutics Inc (BEAM) PT Raised to $35 at RBC Capital
-
Beam Therapeutics Inc (BEAM) PT Raised to $57 at Wedbush
-
Beam Therapeutics Inc (BEAM) PT Raised to $44 at JPMorgan
-
Form S-8 Beam Therapeutics Inc.
-
Form 10-K Beam Therapeutics Inc. For: Dec 31
-
Form 8-K Beam Therapeutics Inc. For: Feb 27
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
-
Form 4 Beam Therapeutics Inc. For: Feb 13 Filed by: FMR LLC
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: ARCH Venture Fund IX, L.P.
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: VANGUARD GROUP INC
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: FMR LLC
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: Temasek Holdings (Private) Ltd
-
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Form 4 Beam Therapeutics Inc. For: Jan 31 Filed by: Evans John M.
-
Form 4 Beam Therapeutics Inc. For: Jan 31 Filed by: Burrell Terry-Ann
-
Form 4 Beam Therapeutics Inc. For: Jan 31 Filed by: Bellon Christine
-
Form 4 Beam Therapeutics Inc. For: Jan 31 Filed by: Simon Amy
-
Form 4 Beam Therapeutics Inc. For: Jan 31 Filed by: Ciaramella Giuseppe
-
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC
-
JPMorgan Upgrades Beam Therapeutics Inc (BEAM) to Overweight
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: BlackRock Inc.
Back to BEAM Stock Lookup